Welcome to our dedicated page for Neurosense Therapeutics SEC filings (Ticker: NRSN), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Digging through NeuroSense Therapeutics’ biotech disclosures can feel like decoding a lab notebook. Clinical trial updates, burn-rate projections, and patent notes sprawl across hundreds of pages, making it hard to spot what matters before the next ALS data milestone. Stock Titan solves this problem by turning every new NeuroSense Therapeutics SEC filing into an easy-to-read brief the moment it hits EDGAR.
Need the NeuroSense Therapeutics quarterly earnings report 10-Q filing to compare R&D spend, or the latest 8-K material events explained after a PrimeC trial update? Our platform delivers AI-powered summaries, red-flag highlights, and side-by-side comparisons. Get NeuroSense Therapeutics insider trading Form 4 transactions and Form 4 insider transactions real-time so you can monitor when executives adjust their holdings ahead of key readouts. You’ll also find the NeuroSense Therapeutics annual report 10-K simplified, complete with context on pipeline progress, cash runway, and intellectual-property status—all without reading every footnote.
Whether you’re tracking NeuroSense Therapeutics earnings report filing analysis, checking a proxy statement executive compensation section, or simply understanding NeuroSense Therapeutics SEC documents with AI, Stock Titan keeps you ahead. Investors use our real-time alerts to follow NeuroSense Therapeutics executive stock transactions Form 4, gauge dilution risk from S-3 shelves, and see how fresh capital supports the multicenter PARADIGM trial. Every filing type—10-K, 10-Q, 8-K, S-1, DEF 14A—is indexed, timestamped, and translated into plain language, so you spend time making decisions, not parsing biotech jargon.
NeuroSense Therapeutics Ltd. (NRSN) submitted a Form 6-K as a foreign private issuer, mainly to furnish materials for an upcoming shareholder vote. The filing attaches a Notice and Proxy Statement for a special meeting of shareholders scheduled for December 30, 2025, along with a proxy card that shareholders can use to cast their votes.
The company also states that this Form 6-K is incorporated by reference into its existing shelf and employee benefit registration statements on Form S-8 and Form F-3. This linkage means the information in this report is now legally part of those registration statements, which can be relevant for future securities offerings and equity compensation plans.
NeuroSense Therapeutics Ltd. filed a Form F-3 to register 333,334 ordinary shares for resale by the selling shareholder. These shares were issued in a September 2025 private placement under a purchase agreement. We will not receive any proceeds from sales by the selling shareholder; they bear the sale decisions and receive all proceeds.
As context, the company had 29,550,970 ordinary shares outstanding as of October 27, 2025. The September 2025 private placement priced shares at $1.50 for gross proceeds of approximately $0.5 million. NeuroSense’s ordinary shares and warrants trade on Nasdaq as NRSN and NRSNW; on October 27, 2025, NRSN closed at $1.14. The prospectus permits various sale methods by the selling shareholder and does not obligate any sale.
NeuroSense Therapeutics Ltd. reports limited clinical survival outcomes and filing cross-references. In the sample presented, 50% (15 of 30) of participants originally randomized to the investigational treatment PrimeC remain alive, while approximately 7% (1 of 14) of participants originally randomized to placebo remain alive. The report also incorporates references to Form S-8 (File No. 333-262480) and multiple Form F-3 filings (File Nos. 333-269306, 333-260338, 333-283656 and 333-284051) to be part of the report from the submission date, subject to any later superseding documents. The filing is signed by CEO Alon Ben-Noon.
NeuroSense Therapeutics Ltd. submitted a Form 6‑K reporting that certain registration statements (Form S‑8 and multiple Form F‑3 filings) are incorporated by reference. The report attaches a Form of Securities Purchase Agreement dated September 4, 2025 between NeuroSense and the purchaser named on the signature pages, and a Press Release dated September 4, 2025. The filing is signed by Alon Ben‑Noon, Chief Executive Officer.
NeuroSense reported a statistically significant clinical benefit for PrimeC at 18 months. An NfL-adjusted MMRM analysis showed a p=0.03 result, corresponding to a 28% relative difference in decline on the ALS Functional Rating Scale-Revised (ALSFRS-R) favoring patients who received PrimeC from study start versus those who began with placebo and switched to PrimeC after six months. The company states these data underscore the clinical importance of initiating PrimeC early in disease progression.
FAQ
What is the current stock price of Neurosense Therapeutics (NRSN)?
What is the market cap of Neurosense Therapeutics (NRSN)?
